The Prognostic Value of Serum Biomarkers in Osteosarcoma

Sponsor
Istituto Ortopedico Rizzoli (Other)
Overall Status
Completed
CT.gov ID
NCT05093101
Collaborator
(none)
600
1
5.4
112

Study Details

Study Description

Brief Summary

Observational retrospective cohort study using laboratory data of blood tests prior to surgical and chemotherapy treatment and other histologic, clinical, and instrumental data related to patient history from digitized medical records and analysis of the same as predictors of outcomes.

Condition or Disease Intervention/Treatment Phase
  • Other: case series review of clinical data

Study Design

Study Type:
Observational
Actual Enrollment :
600 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
The Prognostic Value of Serum Biomarkers in Osteosarcoma
Actual Study Start Date :
Jul 12, 2021
Actual Primary Completion Date :
Dec 22, 2021
Actual Study Completion Date :
Dec 22, 2021

Outcome Measures

Primary Outcome Measures

  1. Evaluation of 5-year survival [5 years]

    Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental prognostic factors

Secondary Outcome Measures

  1. Evaluation of the rate of local recurrence [5 years]

    Evaluation of the rate of local recurrence and distant metastasis in relation to histological, laboratory, clinical, and instrumental prognostic factors.

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Osteosarcoma diagnosed at the Pathological Anatomy of the Rizzoli Orthopaedic Institute in Bologna;

  • Minimum 2-year follow-up period;

  • Medical records, complete blood work and instrumental examinations, regular follow-up;

  • Patients with age ≥ 2 years;

Exclusion Criteria:
  • Patients with osteosarcoma who have received medical treatment (surgery, radiotherapy or chemotherapy) in other hospitals prior to admission to our Institute

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Itituto Ortopedico Rizzoli Bologna BO Italy 40136

Sponsors and Collaborators

  • Istituto Ortopedico Rizzoli

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Costantino Errani, Principal Investigator, Istituto Ortopedico Rizzoli
ClinicalTrials.gov Identifier:
NCT05093101
Other Study ID Numbers:
  • ProOsteo
First Posted:
Oct 26, 2021
Last Update Posted:
Apr 5, 2022
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 5, 2022